U.S. Benefits Manager Baulks After Novartis Values Gene Therapy at $4-5 Million

U.S. Benefits Manager Baulks After Novartis Values Gene Therapy at $4-5 Million

Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.

Read More…